These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19845438)

  • 1. Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice.
    Kuze J; Mutoh T; Takenaka T; Morisaki K; Nakura H; Hanioka N; Narimatsu S
    Xenobiotica; 2009 Nov; 39(11):871-80. PubMed ID: 19845438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam.
    Kuze J; Mutoh T; Takenaka T; Oda N; Hanioka N; Narimatsu S
    Xenobiotica; 2013 Jul; 43(7):598-606. PubMed ID: 23282066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
    Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats.
    Matsuda Y; Konno Y; Satsukawa M; Kobayashi T; Takimoto Y; Morisaki K; Yamashita S
    Drug Metab Dispos; 2012 Dec; 40(12):2231-8. PubMed ID: 22930277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam.
    Yuan R; Flockhart DA; Balian JD
    J Clin Pharmacol; 1999 Nov; 39(11):1109-25. PubMed ID: 10579141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
    Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
    Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats.
    Takedomi S; Matsuo H; Yamano K; Yamamoto K; Iga T; Sawada Y
    Drug Metab Dispos; 1998 Apr; 26(4):318-23. PubMed ID: 9531518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
    Lau YY; Okochi H; Huang Y; Benet LZ
    Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent pharmacokinetics of midazolam in rats: influence of hepatic first-pass metabolism.
    Li R; Wang Q; Liu Z; Xie L; Diao Z; Peng Y; Wang G; Sun J
    Xenobiotica; 2023 Mar; 53(3):184-192. PubMed ID: 37042732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam.
    Ochs HR; Greenblatt DJ; Eichelkraut W; Bakker C; Göbel R; Hahn N
    J Pharmacol Exp Ther; 1987 Dec; 243(3):852-6. PubMed ID: 3694534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
    Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
    Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic and intestinal first-pass effects of oltipraz in rats.
    Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG
    Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
    Ogasawara A; Kume T; Kazama E
    Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
    Hirunpanich V; Murakoso K; Sato H
    Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral idazoxan bioavailability in rat. Relevance of intestinal and hepatic first-pass effect.
    Vallès J; Pruñonosa J; Menargues A; Nomen M; Obach R
    Drug Metab Dispos; 1989; 17(6):673-6. PubMed ID: 2575506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.